The Claim
Among US veterans with type 2 diabetes, initiation of GLP-1 receptor agonists is associated with a 14% lower risk of developing any new substance use disorder over a three-year period compared to initiation of SGLT-2 inhibitors, with a net reduction of 6.61 cases per 1000 individuals, indicating a broad preventive effect across multiple substances including alcohol, cannabis, cocaine, nicotine, and opioids.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
For US veterans with type 2 diabetes, starting a GLP-1 drug (like Ozempic) might help lower the chance of developing addiction problems—like with alcohol, drugs, or smoking—over three years compared to starting a different diabetes drug called an SGLT-2 inhibitor.
See the scientific wording
Initiation of GLP-1 receptor agonists is associated with a 14% lower risk of developing any new substance use disorder over three years compared to initiation of SGLT-2 inhibitors among US veterans with type 2 diabetes, with a net reduction of 6.61 cases per 1000 people, suggesting a broad preventive effect across multiple substances including alcohol, cannabis, cocaine, nicotine, and opioids.
What the research says
1 studyThe study found that veterans with type 2 diabetes who started taking GLP-1 drugs were less likely to develop substance use problems over three years compared to those who took SGLT-2 drugs, and the numbers in the claim match the study results exactly.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.